Survival analysis revealed poor overall survival (OS) and progression-free intervals (PFIs) among patients with high SNRPD2-expressing adrenocortical carcinoma, clear cell and chromophobe cell renal carcinomas, low-grade glioma, lung adenocarcinoma, mesothelioma and uveal melanoma; and shorter PFIs among patients with high SNRPD2-expressing renal papillary cell carcinoma and hepatocellular carcinoma (Figure 1b, Table S1). This evidence concerns the gene SNRPD2 and hepatocellular carcinoma.